Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
Why Is Leverage Shares 2x Long BE Daily ETF (BEG) Up +18.76% Today?

Why Is Leverage Shares 2x Long BE Daily ETF (BEG) Up +18.76% Today?

Key Takeaways

  • BEG surged 18.76% to $57.10, versus a prior close of $48.08.
  • The move was driven by a sharp rebound in underlying stock Bloom Energy, which climbed about 9.4%.
  • Investors rotated back in after Thursday's selloff tied to Oracle's Project Jupiter data center concerns faded.
  • The fund's 2x daily leverage mechanically amplified Bloom Energy's recovery.
  • Broader AI-power-demand momentum, index inclusions, and recent contract wins provided support.
  • Investors are watching Bloom Energy's upcoming earnings and large-project execution next.

Opening Summary

The Leverage Shares 2x Long BE Daily ETF (BEG) is a single-stock leveraged fund that seeks to deliver two times (2x) the daily performance of Bloom Energy (BE), the solid-oxide fuel-cell maker powering the AI data-center buildout. In today's session, BEG rose 18.76% to $57.10 from a prior close of $48.08, as Bloom Energy shares rebounded roughly 9.4% to around $291.72. The sharp gain reflected a broad recovery in the underlying stock after Thursday's force-majeure scare, magnified by the fund's leveraged structure.

What Drove the ETF Move Today

A Rebound From Thursday's Oracle-Linked Selloff

The most immediate catalyst was a relief rally. Bloom Energy slumped Thursday after reports that Oracle had triggered a force-majeure clause tied to Project Jupiter, a large New Mexico data-center development expected to draw power from Bloom's fuel-cell technology. Investors worried the development could delay equipment installations and revenue recognition. As those fears eased—with Oracle and site developer Blue Owl Capital signaling the project remains on track—buyers returned, lifting the leveraged fund sharply.

Leverage Amplified the Recovery

Because BEG targets 2x the daily move of Bloom Energy, a roughly 9.4% rise in the underlying translated into an approximate 18.8% gain for the ETF. This amplification works in both directions, which explains the fund's outsized volatility in recent sessions.

AI Power Demand and Fresh Catalysts

Beyond the day-to-day bounce, Bloom Energy continues to benefit from strong demand for on-site power generation serving data centers. Recent positive developments—including a conditional U.S. Army long-term lease award to an Indelible-Bloom coalition, a $6.4 billion Brookfield-led project-financing framework for data centers tied to Meta, American Tower, Equinix, and CoreWeave, and the New Mexico Supreme Court lifting a stay on Oracle's air-permit proceedings—have reinforced the broader bullish narrative supporting the stock and, by extension, BEG.

Which Holdings Contributed Most

BEG does not hold a diversified basket of securities. As a single-stock leveraged ETF, its performance is driven almost entirely by Bloom Energy, typically through equity and derivative exposure designed to produce 2x daily returns. Consequently, Bloom Energy's rebound was effectively the sole contributor to today's gain. The stock's recent S&P 500 inclusion on September 21 and its addition to the FTSE All-World Index have also drawn passive and institutional buying that supports the underlying shares.

Market Context and Trading Activity

Today's move followed a volatile stretch for the underlying name. Bloom Energy has climbed more than 160% year to date, leaving it prone to sharp two-way swings. The leveraged structure of BEG compounds that volatility, and the fund's daily volume has been elevated alongside the heightened price action. The rebound in the fuel-cell leader stood in contrast to the broader tape and to peers such as Plug Power and FuelCell Energy, which have lagged, underscoring that this remains a company-specific, AI-power story rather than a broad sector trade.

What Comes Next for BEG

Investors will monitor whether Bloom Energy can hold its gains now that index-related buying has largely cleared, and whether its delivery pace on large data-center projects matches the market's elevated expectations. Key items on the calendar include the company's next quarterly earnings report and continued updates on the Oracle Project Jupiter timeline and Brookfield financing package. Risks include the fund's high daily leverage, which can magnify losses, as well as execution risk on multi-gigawatt deployments and a demanding valuation. Volatility, in both directions, is likely to remain elevated.

Trending AI Robots

Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to explore algorithm-driven approaches across different markets. Explore the Trending AI Robots page to see which automated strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BEG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for BEG turns positive, indicating new upward trend

BEG saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator turned positive. In 13 of the 13 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BEG moved above its 50-day moving average on September 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BEG crossed bullishly above the 50-day moving average on September 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEG advanced for three days, in 42 of 43 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 38 of 38 cases where BEG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BEG moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 6 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 9 of 9 cases where BEG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BEG broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily levered investment results, before fees and expenses, of two times (200%) of the daily percentage change in the price of the common stock of BE. The fund invests at least 80% of its net assets (plus borrowings for investment purposes) in financial instruments with economic characteristics that, in combination, provide 200% daily leveraged exposure to the price of BE, consistent with the fund’s investment objective. It is non-diversified.
View a ticker or compare two or three
BEG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
www.ThemesETFs.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.